Real-World Data Drives CAR T Treatment Decisions
Payers and providers are using real-world data to identify high-performing treatment centers, reduce administrative bottlenecks, and support value-based contracting arrangements.
In 2017, the first two CAR T-cell therapies - Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) - were approved and have helped to transform treatment for blood cancer.
Since then, the two therapies have been approved for additional indications and five new CAR T-cell therapies have come to market.
As the CAR T pipeline expands into solid tumors and autoimmune diseases, the current infrastructure may struggle to meet increased demand.
Author summary: Real-world data informs CAR T treatment decisions.
More News
- 'Surreal' for Jones to see Cherries' journey in nine years at club
- Who's enrolled in Sioux Falls' public schools
- Windows File Explorer Previews are Vulnerable to NTLM Hash Leakage – How to Stay Safe - Make Tech Easier
- Why investors are betting big on AI-powered health care
- Obituaries – Week of Oct. 27, 2025 - The Observer
- Pre-school praised for 'working hard to improve' with exemplary Ofsted report
- 'What a player': Adams praises Kroupi's mentality - “his ceiling is really high”
- Sixers Bell Ringer: Sixers storm back to shock Wizards in OT and remain unbeaten
- International Court of Justice’s ruling on climate change affirms states’ obligations to human and planetary health